Does palm oil vitamin E reduce the risk of pregnancy induced hypertension

Title:

Does palm oil vitamin E reduce the risk of pregnancy induced hypertension
Does palm oil vitamin E reduce the risk of pregnancy induced hypertension

Creator:

Mahdy, Zaleha Abdullah, Siraj, Harlina Halizah, Khaza'ai, Huzwah, Mutalib, Mohd Sokhini Abdul, Azwar, Muhammad Hatta, Wahab, Marianah Abdul, Dali, Ahmad Zailani Hatta Md, Jaafar, Rohana, Ismail, Nor Azlin Mohd, Jamil, Muhammad Abdul, and Adeeb, Nafisah

Contributor:

Mahdy, Zaleha Abdullah, Siraj, Harlina Halizah, Khaza'ai, Huzwah, Mutalib, Mohd Sokhini Abdul, Azwar, Muhammad Hatta, Wahab, Marianah Abdul, Dali, Ahmad Zailani Hatta Md, Jaafar, Rohana, Ismail, Nor Azlin Mohd, Jamil, Muhammad Abdul, and Adeeb, Nafisah

Identifier:

https://cdk.lib.cas.cz/client/handle/uuid:bmc14059451-adb75f79-188b-476b-b09a-ddc953d06db2
uuid:bmc14059451-adb75f79-188b-476b-b09a-ddc953d06db2
local:bmc14059451
https://www.lfhk.cuni.cz/Faculty/Publications/Acta-Medica/Archive/2013/
local: bmc14059451

Subject:

dospělí, antioxidancia--terapeutické užití, kohortové studie, potravní doplňky, dvojitá slepá metoda, ženské pohlaví, počet těhotenství, lidé, hypertenze indukovaná těhotenstvím--epidemiologie--prevence a kontrola, incidence, oleje rostlin--terapeutické užití, těhotenství, vitamin E--terapeutické užití, and mladý dospělý

Type:

model:article, article, Text, časopisecké články, randomizované kontrolované studie, práce podpořená grantem, and TEXT

Format:

print, text, and regular print

Description:

In view of the high anti-oxidative potential oftocotrienol, the role of the tocotrienol-rich fraction (TRF) of palm oil in preventing pregnancy induced hypertension (PIH) was explored in a randomized double-blind placebo-controlled clinical trial in an urban teaching hospital. Healthy primigravidae were randomized to receive either oral TRF 100 mg daily or placebo, from early second trimester until delivery. Out of 299 women, 151 were randomized into the TRF arm and 148 into the placebo arm. A total of 15 (5.0%) developed PIH. Although there was no statistically significant difference in the incidence of PIH (4/151 or 2.6% in the TRF arm vs. 11/148 or 7.4% in the placebo arm, p = 0.058) between the two arms, there was a tendency towards a lower incidence of PIH in the TRF arm compared to the placebo arm. With TRF supplementation, the relative risk (RR) of PIH was 0.36 (95% CI 0.12-1.09). In conclusion, although TRF from palm oil does not statistically significantly reduce the risk of development of PIH in the population studied, the 64% reduction in incidence of PIH is substantial. The findings warrant further clinical trials, particularly in high risk populations. and ZA. Mahdy, HH. Siraj, H. Khaza'ai, MS. Mutalib, MH. Azwar, MA. Wahab, AZ. Dali, R. Jaafar, NA. Ismail, MA. Jamil, N. Adeeb

Language:

English

Rights:

http://creativecommons.org/publicdomain/mark/1.0/
policy:public

Relation:

Acta medica (Hradec Králové) / Universitas Carolina, Facultas Medica Hradec Králové--MED00010947

Source:

Acta medica (Hradec Králové) | 2013 Volume:56 | Number:3

Harvested from:

CDK

Metadata only:

false

Date:

2013